About

Yanlan Liu is an Adjunct Faculty member at the School of Earth Sciences at The Ohio State University. She holds a Ph.D. from Duke University, earned in 2019. Her research focuses on understanding how plants respond to climate variations and change, with particular emphasis on drought conditions. Dr. Liu combines physically-based models and data-driven analytics to study a variety of ecosystems, including wetlands, forests, and deserts, spanning from site-specific to continental scales. Her work aims to enhance the understanding of ecohydrology, vegetation dynamics, remote sensing, hydrology and water resources, and environmental statistics.

Research topics

• Internal medicine
• Medicine
• Immunology
• Oncology
• Biology
• Cancer research
• Gastroenterology

Selected publications

• List of contributors

  Elsevier eBooks · 2026-01-01

  book-chapter
  PublisherDOI

• [Study on the regulation mechanism of IL-17 signaling pathway and its intervention strategy in inflammatory diseases].

  PubMed · 2026-03-01

  article1st authorCorresponding

  The interleukin 17 (IL-17) signaling pathway plays a crucial role in the pathogenesis of various inflammation-related diseases and tumours. The IL-17 family of cytokines, particularly IL-17A, has been extensively studied, revealing its pro-inflammatory effects and dual-role in immune responses. Recent studies have shown that IL-17 not only promotes the progression of autoimmune diseases such as psoriasis and ankylosing spondylitis but also facilitates tumour development by regulating immune escape mechanisms within the tumour microenvironment. Although therapeutic strategies targeting IL-17 have shown promising clinical potential, the differences in their effects across various patients and disease states require further investigation. This review will discuss the biological functions of the IL-17 signaling pathway, its dual-role in various diseases, as well as the challenges posed by current targeted therapies and future research directions.

  Publisher

• Evolutionary trajectory and co-infection dynamics of human influenza A(H1N1) virus (2000–2025): an integrated framework informed by expert-informed bibliometrics

  Frontiers in Microbiology · 2026-03-26

  articleOpen access

  Introduction: Influenza A (H1N1) remains an important seasonal respiratory pathogen, but evidence on its evolutionary dynamics, reported co-detections, and surveillance priorities remains fragmented. Methods: We conducted an evidence-mapping synthesis (2000-2025) integrating bibliometric analysis, expert-guided curation, and sequence/structure-informed interpretation. A total of 15,028 records were retrieved from PubMed, Web of Science, and Scopus, and 11,848 unique publications were retained after deduplication. GenBank-derived hemagglutinin (HA) sequences and Swiss-Model homology models were used to characterize mutational patterns and structural features. Literature-derived co-detection records were extracted from eligible publications and interpreted using a method-aware framework. Results: A post-2010 shift in the HA mutational landscape was observed, with recurrent substitutions at sites including S13, S146, S160, and S202. Structure-informed comparison of representative HA models identified a conformationally flexible segment spanning residues aa190-aa226, suggesting potential relevance to the receptor-binding microenvironment. Mapping of literature-derived co-detection records showed that RSV and SARS-CoV-2 were among the most frequently reported co-pathogens; however, these proportions reflected reporting composition across heterogeneous studies rather than population-level co-infection prevalence. In a China-focused module, G219A in Eurasian avian-like (EA) H1N1 strains was prioritized through protocol-constrained expert annotation requiring isolate-level evidence and was interpreted as a hypothesis-generating site of interest within the receptor-binding region rather than an algorithm-derived global bibliometric signal. Discussion: This study provides an integrated overview of H1N1 research evolution, HA mutational change, and reported co-detection patterns over the past 25 years. The findings support a tiered, method-aware multi-pathogen surveillance framework for preparedness, while underscoring that heterogeneous literature-derived co-detection data require standardized definitions, assay-aware interpretation, and local calibration before translation into clinical or public health decision-making.

  PublisherOA PDFDOI

• Wnt-presenting materials sustain H3K14-acetylation in human skeletal stem cells for tissue engineering and bone repair

  bioRxiv (Cold Spring Harbor Laboratory) · 2025-12-19

  articleOpen access

  Engineering functional tissues for transplantation requires insight into epigenetic mechanisms that regulate stem cell fate. We have developed the Wnt-induced osteogenic tissue model (WIOTM), a platform that recapitulates human osteogenesis, and identified acetylation of histone H3 at lysine 14 (H3K14ac) as a critical epigenetic regulator in human skeletal stem cells (hSSCs). In WIOTM, localized Wnt signals drive asymmetric cell division (ACD), yielding a proximal hSSC with high H3K14ac and a distal daughter with reduced H3K14ac that migrates into the 3D collagen matrix and initiates osteogenic differentiation. Disrupting H3K14ac in hSSCs abrogates ACD and WIOTM formation. To test whether hSSCs maintain H3K14ac in vivo , we formed the WIOTM on Wnt-functionalized polymer bandages and transplanted them into calvarial defects. The WIOTM contributed to bone repair, and human cells adjacent to the bandages retained high H3K14ac despite the injury environment. These findings establish WIOTM as both a mechanistic and translational platform for regenerative medicine.

  PublisherOA PDFDOI

• Prognostic Prediction of Advanced Intrahepatic Cholangiocarcinoma Patients Receiving Chemotherapy Combined with Immunotherapy Based on Serum Lipid Profiles

  Research Square · 2025-11-13

  preprintOpen access
  PublisherOA PDFDOI

• Influence of low transformation temperature (LTT) welding consumable on microstructure and deformation behavior of welded joint

  Research Square · 2025-11-27

  preprintOpen access
  PublisherOA PDFDOI

• CHG combined with venetoclax and azacytidine as induction chemotherapy in acute myeloid leukemia

  Blood · 2025-11-03

  articleOpen access

  Abstract Background: The survival rate of patients diagnosed with acute myeloid leukemia (AML) has shown improvement in recent decades. However, the induction chemotherapy regimen for AML still relies on the standard 7+3 regimen. Standard 7+3 regimen can achieve a complete response (CR) rate of 70%-80% in AML patients up to 60 years of age and 50% in older patients. After years of development, the CR rate has shown improvement in both young and elderly AML patients. However, more than 20%-30% of patients still fail to achieve a response after induction chemotherapy, particularly among elderly patients who are deemed unfit. Based on this premise, we endeavored to develop a low-dose, long-course CHG regimen (cytarabine, homoharringtonine, and granulocyte stimulating factor) in combination with the demethylating agent azacytidine and the Bcl-2 inhibitor venetoclax as an induction regimen(NCT06470841). Our aim is to investigate a more efficient and safer induction chemotherapy regimen. Methods: Adult patients with AML were enrolled to receive VACHG induction chemotherapy treatment (venetoclax 100mg po qd d1, 200mg po qd d2, 400mg po qd d3-14; azacytidine 75 mg/m2 subcutaneous injection qd d1-7; homoharringtonine 1mg/m2 iv qd d1-14; cytarabine 10mg/m2 subcutaneous injection q12h d1-14; granulocyte stimulating factor 250ug/m2 subcutaneous injection qd d0-14). After induction therapy, patients will be given standardized treatment according to risk stratification according to NCCN guidelines (NCT06470841). Results: We have currently enrolled a total of 5 patients with acute myeloid leukemia. Among them, 3 patients were over 65 years of age with newly diagnosed acute myeloid leukemia, while the remaining 2 patients were under 60 years of age with refractory/refractory acute myeloid leukemia. One patient achieved CRi after receiving daunorubicin plus cytarabine (DA) induction chemotherapy. However, the patient relapsed after completing 2 courses of consolidation chemotherapy (1 course of DA and 1 course of venetoclax + azacytidine + sorafenib). The patient then obtained CR after completing 1 course of VACHG reinduction chemotherapy. In another patient, non-response (NR) was observed after 1 course of idarubicin plus cytarabine. After the second course of venetoclax + azacytidine(VA) induction chemotherapy, the patient still achieved NR. Then, the patient underwent treatment with the VACHG regimen and achieved CR after a single course of induction chemotherapy using the VACHG regimen. Three additional elderly patients, who were newly diagnosed with AML, achieved a complete response after receiving a single course of VACHG chemotherapy. All the 2 refractory/relapsed AML patients and 3 newly diagnosed elderly AML patients achieved complete remission by a single course of VACHG induction chemotherapy. Grade Ⅳ myelosuppression and infection were observed in all five patients. Two patients experienced gastrointestinal hemorrhage, while one patient suffered from acute kidney injury. Side effects were effectively managed. Following the achievement of complete response, the two refractory/relapsed patients underwent allogeneic hematopoietic stem cell transplantation. The three elderly patients received consolidation and maintenance therapy after achieving complete response. Conclusion: In this trial, we utilized a low-dose, long-course regimen of CHG in combination with the demethylating drug azacytidine and the Bcl-2 inhibitor venetoclax as an induction regimen. Notably, all 5 patients achieved complete remission by a single course of VACHG induction chemotherapy, and the combined chemotherapy regimen demonstrated excellent tolerance in both young and elderly patients. This combined chemotherapy regimen demonstrated remarkable efficacy and merits further implementation. Further enrollment of more patients is necessary to better clarify the effectiveness and safety of VACHG regimen as induction chemotherapy in AML patients.

  PublisherOA PDFDOI

• Indirubin inhibits cervical cancer by inhibiting apoptosis and autophagy through the PI3K/AKT and MAPK pathways

  Research Square · 2025-11-12

  preprintOpen accessSenior author
  PublisherOA PDFDOI

• The changes of CD47 and PD-L1 (SP142) before and after neoadjuvant therapy help predict prognosis of patients with stage IIIA-N2 non-small cell lung cancer

  International Journal of Clinical Oncology · 2025-11-27

  article
  PublisherDOI

• Cathepsin B as a potential serum biomarker for early diagnosis and progression of diabetic foot ulcer complicated with peripheral vascular disease

  Scientific Reports · 2025-11-27 · 1 citations

  articleOpen access

  The existing diagnostic methods of diabetic foot ulcer (DFU) complicated with peripheral vascular disease (PVD) lack sufficient potential for early identification, which leads to slow wound healing, amputation and even death. Thus, this study aimed to explore the potential serum biomarkers of DFU complicated with PVD. A target gene of DFU complicated with PVD was identified using single-cell transcriptome analysis. The immunohistochemistry, ELISA, clinical correlation analysis, tubulogenesis assay, CCK8 assay, and scratch assay were used to verify the correlation between this target gene and DFU complicated with PVD. The ELISA experiment was used to detect the target gene in serum. In this study, the result of PPI in single-cell transcriptomes showed that cathepsin B (CTSB) was enriched in vascular endothelial cells of DFU. The immunohistochemistry and ELISA results revealed that CTSB was highly expressed in the tissues and serum of patients with the combination of DFU and PVD, and this expression increased with the increase of the Wagner grade of DFU. Clinical correlation analysis indicated that CTSB expression is positively correlated with the clinical indicators of the combination of DFU and PVD. Knockdown of CTSB promoted tubulogenesis, proliferation and migration of vascular endothelial cells and overexpression of CTSB has the opposite effect. CTSB, a secretory protein, can be detected as a diagnostic biomarker in serum. Therefore, this study suggested that CTSB can be used as a potential serum diagnostic biomarker for DFU complicated with PVD, which is helpful for the early diagnosis of this disease, prognosis monitoring and adjustment of treatment plans.

  PublisherOA PDFDOI

Recent grants

• NIH Grant R01CA112001

  NIH · $1.3M · 2011

• NIH Grant R01AI051342

  NIH · $1.6M · 2007

• NIH Grant U01CA183030

  NIH · $2.3M · 2018

• NIH Grant R01CA120901

  NIH · $1.6M · 2012

• NIH Grant R41CA093107

  NIH · $165k · 2003

Frequent coauthors

• Pan Zheng

  458 shared

• Sydney C. Ludvigson

  225 shared

• Francisco Palomino

  225 shared

• Andrea Tamoni

  Financial Research (Hungary)

  225 shared

• Leonid Kogan

  Massachusetts Institute of Technology

  225 shared

• Andres Donangelo

  University of Delaware

  225 shared

• Yu Xu

  University of Delaware

  225 shared

• Jianjun Miao

  Boston University

  225 shared

Education

• Post-Doctoral Fellow, Immunobiology Section

  Yale University

  1991

• Ph.D., Department of Immunology

  Australian National University

  1988

• M.S., Microbiology and Immunology

  Chinese Academy of Medical Sciences and Peking Union Medical College

  1985

• BS, Department of Microbiology

  Wuhan University

  1982